JP7532718B2 - 物質のa2-73結晶多形組成物およびそれらの使用方法 - Google Patents

物質のa2-73結晶多形組成物およびそれらの使用方法 Download PDF

Info

Publication number
JP7532718B2
JP7532718B2 JP2020555811A JP2020555811A JP7532718B2 JP 7532718 B2 JP7532718 B2 JP 7532718B2 JP 2020555811 A JP2020555811 A JP 2020555811A JP 2020555811 A JP2020555811 A JP 2020555811A JP 7532718 B2 JP7532718 B2 JP 7532718B2
Authority
JP
Japan
Prior art keywords
free base
dosage form
acid
pharmaceutical formulation
crystalline
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2020555811A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521188A (ja
Inventor
ユー. ミスリング、クリストファー
セルヴェイ、アラーニ
Original Assignee
アナベックス ライフ サイエンス コーポレイション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by アナベックス ライフ サイエンス コーポレイション filed Critical アナベックス ライフ サイエンス コーポレイション
Publication of JP2021521188A publication Critical patent/JP2021521188A/ja
Priority to JP2024016033A priority Critical patent/JP7758768B2/ja
Application granted granted Critical
Publication of JP7532718B2 publication Critical patent/JP7532718B2/ja
Priority to JP2025105737A priority patent/JP2025131907A/ja
Priority to JP2025171096A priority patent/JP2026004574A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Furan Compounds (AREA)
JP2020555811A 2018-04-12 2019-04-12 物質のa2-73結晶多形組成物およびそれらの使用方法 Active JP7532718B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2024016033A JP7758768B2 (ja) 2018-04-12 2024-02-05 物質のa2-73結晶多形組成物およびそれらの使用方法
JP2025105737A JP2025131907A (ja) 2018-04-12 2025-06-23 物質のa2-73結晶多形組成物およびそれらの使用方法
JP2025171096A JP2026004574A (ja) 2018-04-12 2025-10-09 物質のa2-73結晶多形組成物およびそれらの使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862656435P 2018-04-12 2018-04-12
US62/656,435 2018-04-12
PCT/US2019/027369 WO2019200345A1 (en) 2018-04-12 2019-04-12 A2-73 crystalline polymorph compositions of matter and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024016033A Division JP7758768B2 (ja) 2018-04-12 2024-02-05 物質のa2-73結晶多形組成物およびそれらの使用方法

Publications (2)

Publication Number Publication Date
JP2021521188A JP2021521188A (ja) 2021-08-26
JP7532718B2 true JP7532718B2 (ja) 2024-08-14

Family

ID=68163817

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020555811A Active JP7532718B2 (ja) 2018-04-12 2019-04-12 物質のa2-73結晶多形組成物およびそれらの使用方法
JP2024016033A Active JP7758768B2 (ja) 2018-04-12 2024-02-05 物質のa2-73結晶多形組成物およびそれらの使用方法
JP2025105737A Pending JP2025131907A (ja) 2018-04-12 2025-06-23 物質のa2-73結晶多形組成物およびそれらの使用方法
JP2025171096A Pending JP2026004574A (ja) 2018-04-12 2025-10-09 物質のa2-73結晶多形組成物およびそれらの使用方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2024016033A Active JP7758768B2 (ja) 2018-04-12 2024-02-05 物質のa2-73結晶多形組成物およびそれらの使用方法
JP2025105737A Pending JP2025131907A (ja) 2018-04-12 2025-06-23 物質のa2-73結晶多形組成物およびそれらの使用方法
JP2025171096A Pending JP2026004574A (ja) 2018-04-12 2025-10-09 物質のa2-73結晶多形組成物およびそれらの使用方法

Country Status (7)

Country Link
US (3) US11498908B2 (cg-RX-API-DMAC7.html)
EP (1) EP3773531A4 (cg-RX-API-DMAC7.html)
JP (4) JP7532718B2 (cg-RX-API-DMAC7.html)
CN (1) CN112105349A (cg-RX-API-DMAC7.html)
AU (2) AU2019253028B2 (cg-RX-API-DMAC7.html)
CA (2) CA3096671C (cg-RX-API-DMAC7.html)
WO (1) WO2019200345A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025131907A (ja) * 2018-04-12 2025-09-09 アナベックス ライフ サイエンス コーポレイション 物質のa2-73結晶多形組成物およびそれらの使用方法

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021158586A1 (en) 2020-02-04 2021-08-12 Teva Pharmaceuticals International Gmbh Solid state forms of blarcamesine salts
JP2025514292A (ja) * 2022-04-29 2025-05-02 ▲蘇▼州科睿思制▲葯▼有限公司 塩酸ブラルカメシンの結晶形、その調製方法およびその使用
US12018005B1 (en) 2023-07-25 2024-06-25 Egis Gyógyszergyár Zrt. Blarcamesine co-crystals for the manufacture of pharmaceutical dosage form

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017013498A2 (en) 2015-07-22 2017-01-26 Anavex Life Sciences Corp. Crystal forms of tetra-hydro-n, n-dimethyl-2, 2-diphenyl-3-furanmethanamine hydrochloride, processes for making such forms, and their pharmaceutical compositions

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR1002616B (el) * 1996-02-21 1997-02-20 Συνθεση και μεθοδος συνθεσης μοριου: τετραυδρο-ν,ν-διμεθυλο-2,2-διφαινυλο-3-φουρανομεθαναμινης (αε 37), αντισπασμωδικης, αντικαταθλιπτικης και νοοτροπικης δρασης.
AU2011267474B2 (en) * 2010-06-15 2016-05-26 Grünenthal GmbH Pharmaceutical combination for the treatment of pain
WO2014159814A1 (en) * 2013-03-13 2014-10-02 Patricia Oliver Formulations and tablets for treatment or prevention of neurological disorders
GR1008233B (el) * 2013-03-28 2014-06-23 Αλεξανδρος Δημητριου Βαμβακιδης Βελτιωση και θεραπευτικη αξιοποιηση της συμπτωματικης αντιμετωπισης της ασθενειας του alzheimer με rivastigmine, galantamine ή donepezil, δια επιλεγμενων αμινοτετραϋδροφουρανιων που δρουν σαν μικτοι σιγμα-1/ μουσκαρινικοι προσδετες
AU2016248376B2 (en) * 2015-04-15 2020-10-08 Beone Medicines I Gmbh Maleate salts of a B-RAF kinase inhibitor, crystalline forms, methods of preparation, and uses therefore
MX388953B (es) * 2015-05-20 2025-03-20 Ube Industries Cristal de sal de derivado de 3-azabiciclo[3.1.0]hexano novedoso y usos medicionales del mismo.
US11617734B2 (en) * 2015-07-22 2023-04-04 Anavex Life Sciences Corp. Enantiomers of A2-73, analogues, and sigma agonist activity
JP6866379B2 (ja) * 2016-01-26 2021-04-28 アナベックス ライフ サイエンシズ コーポレイション 神経発達障害療法
WO2017172784A1 (en) * 2016-03-28 2017-10-05 Intra-Cellular Therapies, Inc. Novel salts and crystals
CN111315375A (zh) * 2017-06-14 2020-06-19 阿纳韦克斯生命科学公司 用于治疗阿尔茨海默病的anavex2-73
AU2018375667B2 (en) * 2017-11-28 2023-03-02 Anavex Life Sciences Corp. Sigma-1 receptor agonist systolic blood pressure therapy
CN112105349A (zh) * 2018-04-12 2020-12-18 阿纳韦克斯生命科学公司 A2-73结晶多晶型物质组合物及其使用方法

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017013498A2 (en) 2015-07-22 2017-01-26 Anavex Life Sciences Corp. Crystal forms of tetra-hydro-n, n-dimethyl-2, 2-diphenyl-3-furanmethanamine hydrochloride, processes for making such forms, and their pharmaceutical compositions

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025131907A (ja) * 2018-04-12 2025-09-09 アナベックス ライフ サイエンス コーポレイション 物質のa2-73結晶多形組成物およびそれらの使用方法

Also Published As

Publication number Publication date
JP2021521188A (ja) 2021-08-26
AU2024205423B2 (en) 2026-06-25
JP2025131907A (ja) 2025-09-09
US20230142424A1 (en) 2023-05-11
US11498908B2 (en) 2022-11-15
EP3773531A4 (en) 2021-06-23
AU2019253028A1 (en) 2020-10-15
CA3256071A1 (en) 2025-10-31
US12180174B2 (en) 2024-12-31
AU2019253028B2 (en) 2024-05-30
AU2024205423A1 (en) 2024-08-22
US20250115566A1 (en) 2025-04-10
JP2024038524A (ja) 2024-03-19
JP7758768B2 (ja) 2025-10-22
EP3773531A1 (en) 2021-02-17
US20210115004A1 (en) 2021-04-22
JP2026004574A (ja) 2026-01-14
CA3096671A1 (en) 2019-10-17
WO2019200345A1 (en) 2019-10-17
CN112105349A (zh) 2020-12-18
CA3096671C (en) 2025-09-16

Similar Documents

Publication Publication Date Title
JP7758768B2 (ja) 物質のa2-73結晶多形組成物およびそれらの使用方法
AU2017213475B2 (en) SecA inhibitors and methods of making and using thereof
US20170027873A1 (en) Solid Dispersion Comprising An Orexin Receptor Antagonist
EA019689B1 (ru) Бензолсульфонат 2-[[[2-[(гидроксиацетил)амино]-4-пиридинил]метил]тио]-n-[4-(трифторметокси)фенил]-3-пиридинкарбоксамида, его кристаллы, его полиморфы и способы их получения
CN106957315B (zh) N-取代苯磺酰基-氮杂吲哚氧基苯甲酰胺类化合物及其制备药物的用途
BR112019010816A2 (pt) composto de fórmula i, composto de fórmula ii, composto de fórmula iii, composto de fórmula iv, composto de fórmula v, composição farmacêutica, compostos, composto de fórmula viii, composto de fórmula ix, e composto de fórmula x
CN100445288C (zh) 银杏内酯b衍生物及其在制药中的应用
AU2014222362B2 (en) Formulation comprising benzothiazolone compound
RU2341529C2 (ru) Гликозидное пролекарство 5-аминосалициловой кислоты
AU2018325267B2 (en) Crystalline forms of compounds for preventing or treating sensory hair cell death
KR20150127483A (ko) 몬테루카스트 또는 이의 약제학적으로 허용가능한 염을 포함하는 안정성이 개선된 액상 제제 및 이의 제조방법
US20160046611A1 (en) Novel chromone alkaloid dysoline for the treatment of cancer and inflammatory disorders
JP2022554159A (ja) Gabaa受容体モジュレーターによるてんかん状態の治療
WO2012023145A2 (en) Prasugrel hydrochloride crystalline particles
JP2025525799A (ja) 変性疾患によって引き起こされる認知低下の予防のための組成物及び方法
CN115813897A (zh) 克罗米通及其衍生物的抗衰老用途
CN106588775A (zh) 一种吲唑衍生物及其制备方法和应用
HK1206736B (en) Seca inhibitors and methods of making and using thereof
HK1212213B (en) Formulation comprising benzothiazolone compound

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220407

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230120

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230120

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230309

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230418

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230718

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240205

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240304

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240322

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20240702

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20240708

R150 Certificate of patent or registration of utility model

Ref document number: 7532718

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150